NovoCure Appoints New President at Annual Meeting

The latest announcement is out from NovoCure ( (NVCR) ).

On June 4, 2025, NovoCure held its annual general meeting where shareholders elected eleven directors to serve until the 2026 meeting, with no third-party arrangements involved. Additionally, Francis Leonard was appointed as President of NovoCure and awarded Restricted Share Units under the company’s incentive plan. The meeting also saw the approval of several proposals, including the ratification of the company’s independent auditor, a non-binding advisory vote on executive compensation, and the approval of the 2025 Employee Share Purchase Plan.

The most recent analyst rating on (NVCR) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.

Spark’s Take on NVCR Stock

According to Spark, TipRanks’ AI Analyst, NVCR is a Neutral.

NovoCure’s stock score reflects the company’s strategic growth initiatives and positive trial results but is weighed down by financial challenges, including losses and cash flow issues. The technical analysis and valuation further contribute to a moderate outlook.

To see Spark’s full report on NVCR stock, click here.

More about NovoCure

NovoCure Limited operates in the medical technology industry, focusing on the development and commercialization of innovative therapies for solid tumor cancers. The company’s primary product is the Optune system, a wearable device that uses electric fields to disrupt cancer cell division, offering a novel approach to cancer treatment.

Average Trading Volume: 976,256

Technical Sentiment Signal: Sell

Current Market Cap: $1.86B

See more insights into NVCR stock on TipRanks’ Stock Analysis page.